2013

2013

2013

April 18, 2013

Harvard-led researchers offer potential new treatments for subtype of acute myeloid leukemia

December 23, 2013

An international team of researchers working in the Boston and Singapore labs of Harvard Stem Cell Institute (HSCI) Blood Program leader Daniel Tenen, MD, recently identified new candidates for the treatment of an acute myeloid leukemia (AML) subtype caused by mutations of CEBPA, a tumor suppressor. The findings were published in two separate studies:… Read more about Harvard-led researchers offer potential new treatments for subtype of acute myeloid leukemia

New research implicates immune system cells in muscle healing

December 20, 2013

Harvard stem cell scientists have found that cells known primarily for tempering immune response also exist in injured muscle tissue, an unexpected role for regulatory T cells.

Regulatory T cells, or Tregs for short, accumulate in the skeletal muscles of mice after injury or after the animals developed muscular dystrophy, the researchers found. Their discovery adds another surprising role to… Read more about New research implicates immune system cells in muscle healing

HSCI Executive Committee member selected to join Biogen Idec's ALS consortium

January 2, 2013

HSCI Executive Committee member Lee Rubin is one of seven scientists selected by biotech leader Biogen Idec to identify and develop new approaches for treating amyotrophic lateral sclerosis (ALS) - more commonly known as Lou Gehrig's disease. Rubin and the other six scientists at Harvard, Yale, Columbia, and Rockefeller will form a consortium to bring to bear their complementary research interests, talents, and areas of expertise on the hitherto untreatable and fatal neurodegenerative disease.

Read more about HSCI Executive Committee member selected to join Biogen Idec's ALS consortium

The New York Stem Cell Foundation awards for early career investigators in translational stem cell research

January 28, 2013

The New York Stem Cell Foundation has announced the 2013 RFA for Innovator Awards for Early Career Investigators in Translational Stem Cell Research, and for the first time, is open to researchers at accredited academic institutions from throughout the world (subject to eligibility).  The goal of these awards is to support the best young researchers working on bold and innovative projects with the potential to transform the field of stem cell research and advance understanding and… Read more about The New York Stem Cell Foundation awards for early career investigators in translational stem cell research

2013 HSCI call for proposals – P01 pilot grants in human cellular pluripotency

February 19, 2013

Application Deadline: Wednesday, April 1, 2013

The Harvard Stem Cell Institute (HSCI) invites applications for Pilot Grant funding for 2013 under the NIH-funded P01 grant "Dissecting the establishment and regulation of human pluripotency" (PI Alex Meissner, Harvard Department of Stem Cell and Regenerative Biology). The purpose of this funding program is to provide resources for proof-of-concept studies. These pilot grants are intended to increase our understanding of the basic biology of human pluripotent cells and their utility for translational… Read more about 2013 HSCI call for proposals – P01 pilot grants in human cellular pluripotency

Company that began with an HSCI seed grant announces $240M investment

March 22, 2013

This week the New York Times published an article announcing a $240M investment by Astra Zeneca in Moderna Therapeutics, a start-up company founded by HSCI Principal Faculty Derrick Rossi. As the Times says, "It is one of the largest ever initial payments in a pharmaceutical industry licensing deal that does not involve a drug already being tested in clinical trials." 

The idea behind the company started several years ago when HSCI funded a project in Rossi's lab focused on using modified RNA to reprogram stem cells. Not only was this successful and a breakthrough in itself, but it… Read more about Company that began with an HSCI seed grant announces $240M investment

Two HSCI leaders ranked in Top 50 in world stem cell influencers

March 26, 2013

When the organizers of the upcoming World Regenerative Medicine Congress recently asked scientists and executives across the world in the stem cell and regenerative medicine fields to name “the most influential people in the global stem cell and cell therapy field,” two of HSCI’s leaders were in the top 11.

Doug Melton, HSCI’s Co-Director and Co-Founder, was named number five on the list of the world’s top 50 “Stem Cell Influencers.”  Melton, who is also co-chair of Harvard’s Department of Stem Cell and Regenerative Biology, was cited as “one of the driving forces behind Read more about Two HSCI leaders ranked in Top 50 in world stem cell influencers

Kevin Eggan named a member of a new Stem Cell Research Consortium

March 26, 2013

HSCI's Kevin Eggan has been named a member of a new Stem Cell Research Consortium established by the Cure Alzheimer's Fund. The six consortium scientists, at academic research institutions in the US and Israel will be using techniques pioneered by Eggan, an HSCI Principal Faculty member and a professor in Harvard's Department of Stem Cell and Regenerative Biology, to study in the laboratory the neurons created from the cells of patients at high genetic risk of developing Alzheimer's.

This approach is one of our best shots at understanding common forms of Alzheimer’s and, once… Read more about Kevin Eggan named a member of a new Stem Cell Research Consortium

Pages